Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Sorrento subsidiary to acquire Scottish biotech Virttu Biologics for $25M in all-stock deal

Published 11/16/2016, 03:47 PM
Sorrento subsidiary to acquire Scottish biotech Virttu Biologics for $25M in all-stock deal
SRNE
-
  • Sorrento Therapeutics (SRNE -4.6%) subsidiary TNK Therapeutics inks an agreement to acquire Glasgow, Scotland-based Virttu Biologics Ltd.
  • Privately held Virttu's lead product candidate is a oncolytic immunotherapy based on a modified version of the human herpes simplex virus (HSV-1) called SEPREHVIR. It is designed to kill cancer cells and elicit an anti-tumor immune response.
  • Under the terms of the agreement, Virttu shareholders will receive $5M in Sorrento stock at closing, expected in Q1 2017, and $20M in TNK stock within 12 months following the next round of financing.


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.